That’s awesome! Something to keep in mind as NeverCides slips under a dime.

USUAlly when a CEO retires on good terms a replacement CEO is already lined up and the press releases has glowing words from both him and the company.

Shit may be about t to hit the fan here.

Subpenny cominh for this scam fraud pile of shit.

IM up a lot more than 539% on ZYXI.

Generally bad news is delayed and good news is eagerly reported early. Also nearly a week heads up is a good sign. Stranger things have happened in the stock market, but it seems like the stars are aligning nicely here.

Regardless of the reasons for NNVC’s embarrassing failure, it should be obvious by now that
snake oil doesn’t work and never will work. There may be additional undisclosed reasons for this, but from an investment perspective it’s pointless to try to piece together why this failed garbage has failed. It has failed miserably.

Nanocancercides.....hmmmm

Brave.

Back over one clam? How long will it hold before the inevitably flush down the biowreck toilet?

NevetCides is toast.

Even a middle schooler saw the clam evaporation coming.

NanoViricides: House Of Cards With -80% Downside, 'Strong Sell' Recommendation

http://seekingalpha.com/article/2010691-nanoviricides-house-of-cards-with-minus-80-percent-downside-strong-sell-recommendation

$10+ ? With more success possibly much higher IMO

"Investor day" I assume is different than a normal conference call. If it's an investor presentation then many of them are indeed four hours and longer.

What's amazing is NNVC isn't 1/10th of clam sooner than it will be.

Ansun BioPharma Announces Breakthrough Designation for its Experimental Drug DAS181

https://www.prnewswire.com/news-releases/ansun-biopharma-announces-breakthrough-designation-for-its-experimental-drug-das181-300533677.html?tc=

"Ansun recently completed a Phase 2 study of DAS181 for treatment of PIV infection in hospitalized, immunocompromised patients and is now in the planning stage of a Phase 3 study. In addition, Ansun has worked in collaboration with the FDA to make DAS181 available for treatment of over 130 pediatric and adult patients through compassionate use under single patient emergency IND applications. "We are excited about this designation and look forward to continuing to work closely with the Division of Antiviral products at the FDA as we plan and implement a Phase 3 study for this severely ill patient population," said Dr. George Wang, Chief Technical Officer of Ansun Biopharma."

Bad guess.

Any updates on the warrant scheme?

Isn't being a shareholder in this ridiculous scam embarrassment enough?

Newmoney is correct as usual as fizzle continues.

The 3.5 year chart isn't exactly a source for bragging points by long-term investors.

Then how come the older Seymour gets the more hot air he barfs up?

More interesting is NNVC is about to lose 1 clam for good.

I couldn't have written that Pump Terminator article better myself. ;)

Nah, your dumping of this one clam scam was wise.

Wise.

In the movie Casino, a pen made a great weapon.

Noted.

Soon there will be an app for that.

Brave.

I hoping for $6 million, and lll be as happy as a pig in shit assuming net income show sequential growth similarly.

Interesting... ZYXI had guided $3.8 million revenue and $500k net income and annihilated those estimates for Q2 with $5 mil rev and $1.5 mil net income.

ZYXI hit $2.50!!! With my average cost under 20 cents I'm cleaning up. Been slowly peeling off shares the last 3 days not because of anything fundamentally wrong, but when one of my biggest positions gains nearly 1150% it's time to take a chunk off the table.

So glad I stuck to my own research and analysis on this one.

2018 is another dead year before it even begins.

Tax loss selling up next.

The only "trials" NNVC is close to are of the criminal variety.

I AM BETTER THAN YOU Member Level Wednesday, 06/22/16 05:01:11 PM
Re: KMBJN post# 122477
Post # of 135200
Common sense says fraud. There is zero chance of trials 2017. Absolutely zero.

Mark this post.

2018 is a dead year before it even begins. I'm sick of being right every single time.

Here's what the brain dead, discredited anonymous coward on Seeking Alpha concluded after visiting the plant last year:

"...as the company completes Toxicity testing for FluCide - likely during early-mid 2016 - most of the remaining risks shadowing NNVC will move to the wayside, and shareholders can expect to see steady returns as Clinical Testing begins, and as the likelihood of a steady revenue stream in the near future increases.


Why is that I figured out this to be total bullshit, and I didn't even have to leave my mom's basement to figure that out?

I didn't need to fly up there -- I said all of 2015 that 2016 will be a dead year with no TOX completed yet again. And, whaddaya know, it's halfway over without TOX anywhere in sight! No car counting necessary.

It seems NNVC is further behind now than the cocksureness of three years ago:

TOX has started,.... and the 200 g was apparently enough for BASi to get the ball rolling.

That's a fact you can't deny,.... try hard as you might.

It is still 2014,.... and TOX has started,.... that's a fact you can't deny,.... so your point about it not getting started until 2015 is also dead.

Has BASi called it 'insufficient' to get started? Has BASi called what was sent a 'sample'? And since they are the experts on doing this sort of work,.... I'll chose to follow their lead here.